The European Medical Association (EMA) has strengthened the mandate for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).  Currently, the mandate works to strengthen how the risks and benefits of medicinal products in Europe are monitored. The EMA has created a COVID-19 Response Group within ENCePP to help in pharmacovigilance and pharmacoepidemiology work during the pandemic. This will be achieved, according to EMA’s announcement on 5/25, by strengthening the capacity of ENCePP to: 

  • facilitate access to high quality data and their analysis to support research and regulatory decisions in relation to the COVID-19 pandemic.  
  • support collaborations aiming to design and conduct high quality multicentre observational research  
  • improve regulatory science by promoting use and dissemination of valid and reliable methodologies appropriate to COVID-19. 

Read more here